Dupilumab, mepolizumab, reslizumab, benralizumab, and more! buff.ly/3IPqVKb Brian Hemstreet, PharmD, FCCP, BCPS ACCP GILN PRN

Evidence supporting multiple biosimilar switches is scarce, but more data is emerging. pubmed.ncbi.nlm.nih.gov/36802176/

New ASPEN-developed practice tool! Dosing Multivitamins in PN Outside of a Shortage: Practicing the Standard of Care nutritioncare.org/uploadedFiles/…

1a) Welcome to our first ever joint #accredited #tweetorial on ibd_ce! You may know us from @cardiomet_ce or @CKD_ce or @onc_ce. We bring expert-authored 🆓CE/#CME to you wholly on Twitter, in a fun and bite-sized exchange. Follow us!

📣 Looking for #CE, #CME credit? ✅ Out this #tweetorial on #IBD and #biosimilars! Had a great time putting this together with AcademicCME Amanuel Kehasse PharmD, PhD and Dr. Cheiftez!

Two live FMT products have been recently FDA approved. Rebyota™ is available as a rectal suspension, and Vowst™ as oral capsules. Both are FDA-approved for the prevention of recurrence of C difficile infection following antibacterial treatment of recurrent infection.

It was a once in a lifetime experience to throw the #FirstPitch at tonight's Miami Marlins game in recognition of #WorldIBDDay. I am so grateful to them and Sherman Prize for joining me in the fight against #IBD. Who knows? I might start a "League of My Own" 😉 Miller Medicine

New milestone in CD therapy 👍

Linaclotide has been FDA approved for the treatment of functional constipation in patients age 6 and older, making it the first approved option for the treatment for pediatric functional constipation! The recommended dose is 72 mcg by mouth once daily.

Updated AASLD-IDSA clinical practice guidelines for the testing and management of hepatitis C! academic.oup.com/cid/advance-ar…

Mirikizumab, an IL-23 inhibitor, may be nearing FDA approval for the treatment of ulcerative colitis. academic.oup.com/ecco-jcc/advan…

Risk stratification for diagnosis and Rxment of metabolic liver disease. Role of non-invasive biomarkers. A clinical practice update from American Gastroenterological Association (AGA) Gastroenterology #NAFLD #NASH

Crohn's and Colitis health providers, the new Health Maintenance Checklist is a must see!

Big news in the IBD world as results from yet another biologic head to head trial were released. This time it was risankizumab compared to ustekinumab. Risankizumab met both primary endpoints of non-inferiority in clinical remission. Check it out below. prnewswire.com/news-releases/…

A promising meta-analysis describing similar rates of malignancies in patients with immune-mediated conditions treated with and without immunosuppressive therapies. pubmed.ncbi.nlm.nih.gov/37579866/

Etrasimod has been approved for the treatment of moderate to severe ulcerative colitis. Check it out! thelancet.com/journals/lance…

Subcutaneous vedolizumab has been recently approved for the treatment of moderately to severely active ulcerative colitis! gastrojournal.org/article/S0016-…

Major update! Subcutaneous infliximab-dyyb has been approved for the maintenance treatment of Crohn's disease and ulcerative colitis. Subcutaneous infliximab-dyyb should be started after completion of IV infusion induction therapy. pharmacytimes.com/view/fda-appro…

sciencedirect.com/science/articl… Vonoprazan has been FDA approved for the treatment and maintenance of erosive esophagitis based on a phase 3 trial demonstrating superiority vs. lansoprazole. Superiority was driven by patients with more severe disease.

Resmetirom is the first medication approved to treat nonalcoholic steatohepatitis! nejm.org/doi/10.1056/NE…